Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 5,200
- Avg volume
- 47,564
- Day's range
- $0.01 – $0.01
- Shares out
- —
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Exousia Bio, Inc., a biotechnology company, designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAM...
Show more
Exousia Bio, Inc., a biotechnology company, designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026. The company was incorporated in 2022 and is based in Saint Petersburg, Florida.
- Industry
- Education & Training Services
- Sector
- Consumer Defensive
- Phone
- 509 605 6533
- Website
- https://exousiabio.com
- Address
- 7901 4th Street N, #23494, Saint Petersburg, United States
Latest news
No headlines yet.
